April D Thames1, Marisa S Briones, Larry I Magpantay, Otoniel Martinez-Maza, Elyse J Singer, Charles H Hinkin, Susan Morgello, Benjamin B Gelman, David J Moore, Keith Heizerling, Andrew J Levine. 1. aDepartment of Psychiatry and Biobehavioral Sciences bDepartment of Family Medicine cDepartment of Obstetrics & Gynecology dDepartment of Epidemiology and Microbiology eDepartment of Immunology & Human Genetics fDepartment of Neurology, University of California, Los Angeles gGreater Los Angeles VA Healthcare System, Los Angeles, California hDepartment of Neurology iDepartment of Pathology jDepartment of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, New York kDepartment of Pathology lDepartment of Neuroscience mDepartment of Cell Biology, University of Texas Medical Branch, Galveston, Texas nDepartment of Psychiatry, University of California, San Diego, California, USA.
Abstract
OBJECTIVES: We examined interrelationships between chemokine C-C motif ligand 2 (CCL2) genotype and expression of inflammatory markers in the cerebrospinal fluid (CSF), plasma viral load, CD4 cell count and neurocognitive functioning among HIV-infected adults. We hypothesized that HIV-positive carriers of the 'risk' CCL2 -2578G allele, caused by a single nucleotide polymorphism (SNP) at rs1024611, would have a higher concentration of CCL2 in CSF, and that CSF CCL2 would be associated with both higher concentrations of other proinflammatory markers in CSF and worse neurocognitive functioning. DESIGN: A cross-sectional study of 145 HIV-infected individuals enrolled in the National NeuroAIDS Tissue Consortium cohort for whom genotyping, CSF and neurocognitive data were available. METHODS: Genomic DNA was extracted from peripheral blood mononuclear cells and/or frozen tissue specimens. CSF levels of CCL2, interleukin (IL)-2, IL-6, tumour necrosis factor-alpha (TNF-α), interferon-gamma (IFN-γ), soluble tumor necrosis factor receptor 2, sIL-6Rα, sIL-2, sCD14 and B-cell activating factor were quantified. Neurocognitive functioning was measured using a comprehensive battery of neuropsychological tests. RESULTS: Carriers of the CCL2 -2578G allele had a significantly higher concentration of CCL2 in CSF. CSF CCL2 level was positively and significantly associated with other CSF neuroinflammatory markers and worse cognitive functioning. There was a significant association between genotype and plasma viral load, such that carriers of the CCL2 -2578G allele with high viral load expressed greater levels of CCL2 and had higher neurocognitive deficit scores than other genotype/viral load groups. CONCLUSION: Individuals with the CCL2 -2578G allele had higher levels of CCL2 in CSF, which was associated with increased pro-inflammatory markers in CSF and worse neurocognitive functioning. The results highlight the potential role of intermediate phenotypes in studies of genotype and cognition.
OBJECTIVES: We examined interrelationships between chemokine C-C motif ligand 2 (CCL2) genotype and expression of inflammatory markers in the cerebrospinal fluid (CSF), plasma viral load, CD4 cell count and neurocognitive functioning among HIV-infected adults. We hypothesized that HIV-positive carriers of the 'risk' CCL2 -2578G allele, caused by a single nucleotide polymorphism (SNP) at rs1024611, would have a higher concentration of CCL2 in CSF, and that CSF CCL2 would be associated with both higher concentrations of other proinflammatory markers in CSF and worse neurocognitive functioning. DESIGN: A cross-sectional study of 145 HIV-infected individuals enrolled in the National NeuroAIDS Tissue Consortium cohort for whom genotyping, CSF and neurocognitive data were available. METHODS: Genomic DNA was extracted from peripheral blood mononuclear cells and/or frozen tissue specimens. CSF levels of CCL2, interleukin (IL)-2, IL-6, tumour necrosis factor-alpha (TNF-α), interferon-gamma (IFN-γ), soluble tumor necrosis factor receptor 2, sIL-6Rα, sIL-2, sCD14 and B-cell activating factor were quantified. Neurocognitive functioning was measured using a comprehensive battery of neuropsychological tests. RESULTS: Carriers of the CCL2 -2578G allele had a significantly higher concentration of CCL2 in CSF. CSF CCL2 level was positively and significantly associated with other CSF neuroinflammatory markers and worse cognitive functioning. There was a significant association between genotype and plasma viral load, such that carriers of the CCL2 -2578G allele with high viral load expressed greater levels of CCL2 and had higher neurocognitive deficit scores than other genotype/viral load groups. CONCLUSION: Individuals with the CCL2 -2578G allele had higher levels of CCL2 in CSF, which was associated with increased pro-inflammatory markers in CSF and worse neurocognitive functioning. The results highlight the potential role of intermediate phenotypes in studies of genotype and cognition.
Authors: L A Ryan; J Zheng; M Brester; D Bohac; F Hahn; J Anderson; W Ratanasuwan; H E Gendelman; S Swindells Journal: J Infect Dis Date: 2001-08-15 Impact factor: 5.226
Authors: Andrew J Levine; Sandra Reynolds; Christopher Cox; Eric N Miller; Janet S Sinsheimer; James T Becker; Eileen Martin; Ned Sacktor Journal: J Neurovirol Date: 2014-04-16 Impact factor: 2.643
Authors: Minh-Hieu T Pham; Gregory B Bonello; John Castiblanco; Tuan Le; Jose Sigala; Weijing He; Srinivas Mummidi Journal: PLoS One Date: 2012-11-16 Impact factor: 3.240
Authors: P Lorenzo Bozzelli; Tao Yin; Valeria Avdoshina; Italo Mocchetti; Katherine E Conant; Kathleen A Maguire-Zeiss Journal: Glia Date: 2019-05-23 Impact factor: 7.452
Authors: C Blokhuis; C F W Peeters; S Cohen; H J Scherpbier; T W Kuijpers; P Reiss; N A Kootstra; C E Teunissen; D Pajkrt Journal: Sci Rep Date: 2019-05-29 Impact factor: 4.379